Related references
Note: Only part of the references are listed.Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis
M. Gillett et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Cost-Effectiveness of Lifestyle Modification in Diabetic Patients
Monique A. M. Jacobs-van der Bruggen et al.
DIABETES CARE (2009)
Efficacy and safety of incretin-based therapies: Clinical trial data
John White
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy
B. Schwarz et al.
DIABETES OBESITY & METABOLISM (2008)
PROactive 06:: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK
W. J. Valentine et al.
DIABETIC MEDICINE (2007)
Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues
Meryl Brod et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Validation of the CORE diabetes model against epidemiological and clinical studies
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Assessing the impact of complications on the costs of Type II diabetes
R Williams et al.
DIABETOLOGIA (2002)
Coping with Type II diabetes: the patient's perspective
M Koopmanschap
DIABETOLOGIA (2002)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
